Fusion-competent vaccines: Broad neutralization of primary isolates of HIV

Current recombinant human immunodeficiency virus (HIV) gp 120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, 'fusion-competent' HIV vaccine immunogens were generated that capture the transient envelope-CD4- coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E. Development of these fusion-dependent immunogens may lead to a broadly effective HIV vaccine.